A series of cardiometabolic-related news items has been observed from EMA, Lilly, Beta Bionics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Lilly announced topline TRIUMPH-1 data with retatrutide exhibiting up to -30% weight loss (view press release); and Bayer’s Kerendia received FDA priority review in T1DM-associated CKD (view press release). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Regeneron posted a Ph1 study of a new obesity asset (view CT.gov record); Vincentage reported positive topline results from the Ph3 obesity study of its oral GLP-1RA (view press release); and Pfizer posted the VESPER-6 study of berobenatide (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from FDA, AstraZeneca, Dexcom, and EMA. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Apotex launched generic semaglutide in Canada (view press release); Roche posted a Ph2 obesity combination study (view CT.gov record); and Lilly posted a new macupatide + eloralintide combination study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.
Dexcom hosted its 2026 Investor Day and provided updates across its diabetes business, including the ongoing launch of the G7 15-day, its next-gen G8 CGM, as well as a new dual glucose-potassium sensor (view slides). Following the call, Dexcom’s stock is up ~6% today. In conjunction with the Investor Day, Dexcom also announced updates to its governance structure, including the planned addition of two new independent board members (view press release). Below are highlights and insights from the investor event.
Two cardiometabolic-related news items have been observed: FDA issued a warning letter to ProRx regarding GLP-1RA compounding (view FDA letter) and Lilly partnered with UNICEF (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from FDA, Novo Nordisk, Altimmune, Lilly, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Fractyl Health, and Roche. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Cytokinetics presented additional aficamten data (view press release), and FDA launched pilot one-day inspectional assessments (view FDA news release). Below, FENIX provides highlights and insights for the respective news items.